$23.20
0.46[2.02%]
At close: Apr 25
$23.20
0[0.00%]
PreMarket: 4:10AM EDT
Beam Therapeutics
(NASDAQ:BEAM)Beam Therapeutics Stock (NASDAQ:BEAM), Analyst Ratings, Price Targets, Predictions
Beam Therapeutics Inc has a consensus price target of $55.81, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, BMO Capital, and Barclays on April 23, 2024, March 27, 2024, and February 28, 2024. With an average price target of $52 between Wedbush, BMO Capital, and Barclays, there's an implied 124.14% upside for Beam Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
BMO Capital
Barclays
RBC Capital
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Beam Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 145.69% | Wedbush | David Nierengarten | → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 145.69% | BMO Capital | Kostas Biliouris | → $57 | Maintains | Outperform | Get Alert |
| 02/28/2024 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 81.03% | Barclays | Gena Wang | $26 → $42 | Maintains | Equal-Weight | Get Alert |
| 02/28/2024 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 50.86% | RBC Capital | Luca Issi | $27 → $35 | Maintains | Sector Perform | Get Alert |
| 01/29/2024 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 72.41% | JP Morgan | Eric Joseph | $38 → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 12/15/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 50.86% | B of A Securities | Greg Harrison | → $35 | Downgrade | Buy → Neutral | Get Alert |
| 12/08/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 29.31% | Jefferies | Michael Yee | $75 → $30 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 37.93% | Cantor Fitzgerald | Rick Bienkowski | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 141.38% | Cantor Fitzgerald | Rick Bienkowski | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 141.38% | Cantor Fitzgerald | Rick Bienkowski | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 50.86% | Barclays | Gena Wang | $41 → $35 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 102.59% | Credit Suisse | Richard Law | $46 → $47 | Maintains | Neutral | Get Alert |
| 08/09/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 141.38% | Citigroup | Samantha Semenkow | $60 → $56 | Maintains | Buy | Get Alert |
| 05/11/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 81.03% | RBC Capital | Luca Issi | $50 → $42 | Maintains | Sector Perform | Get Alert |
| 05/11/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 76.72% | Barclays | Gena Wang | $45 → $41 | Maintains | Equal-Weight | Get Alert |
| 05/11/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 158.62% | Citigroup | Samantha Semenkow | $62 → $60 | Maintains | Buy | Get Alert |
| 03/21/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 59.48% | Bernstein | William Pickering | → $37 | Initiates | → Market Perform | Get Alert |
| 03/01/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 352.59% | Wells Fargo | Yanan Zhu | $125 → $105 | Maintains | Overweight | Get Alert |
| 02/01/2023 | BEAM | Buy Now | Beam Therapeutics | $23.20 | 167.24% | Cantor Fitzgerald | Rick Bienkowski | → $62 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Beam Therapeutics (BEAM)?
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Wedbush on April 23, 2024. The analyst firm set a price target for $57.00 expecting BEAM to rise to within 12 months (a possible 145.69% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Beam Therapeutics (BEAM)?
The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by Wedbush, and Beam Therapeutics reiterated their outperform rating.
When was the last upgrade for Beam Therapeutics (BEAM)?
The last upgrade for Beam Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $40. JP Morgan previously had a neutral for Beam Therapeutics Inc.
When was the last downgrade for Beam Therapeutics (BEAM)?
The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Beam Therapeutics (BEAM) correct?
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a reiterated with a price target of $0.00 to $57.00. The current price Beam Therapeutics (BEAM) is trading at is $23.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.